Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious approach when it comes to buying other companies, which are expensively priced.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

The app attracted a lot of attention during the pandemic as a potentially way to differentiate COVID-19 from other respiratory infections, but Merck says it will use it more generally as a cough ...

Cases of flu, COVID and RSV remain high across the U.S., CDC data shows. Respiratory viruses are continuing to spread across the United States, sickening millions of Americans. Overall respiratory ...

Frespaciguat is under clinical development by Merck and currently in Phase II for Pulmonary Hypertension. According to GlobalData, Phase II drugs for Pulmonary Hypertension have a 58% phase transition ...